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Objectives: Essential Hypertension (EHT) is described as sailent killer as it is 
almost symptomless.However mild symptoms like headache, loss of sleep, gid-
diness, redness in the eye and restlessness comprise of morbidity. In this study 
Gandharvahasthadi Kashayam (GK) consisting of polyherbal meidicines was studied 
in the manAgement of EHT. MethOds: The case control study was adminsitred 
for 30 patients who were diagonosed with EHT .For one month, Each patient was 
administred 15 ml bid with GK, half an hour before food. Systolic Blood Pressure 
(SBP) was in the range of 140-160 and Diastolic(DBP) was 90 to 100 were inclluded in 
the study. The morbidity was scored by history taking. Results: After one month 
The SBP was 126 -136 and DBP 80- 86; the headache was relived in in 15 patients, 
improvement in loss of sleep reported in 22 patients, redness in the eye was relived 
2 patient out of 5 . 20 patients expressed relief rom restlessness. cOnclusiOns: 
The GK is found to control SBP and DBP in all patients studied. In addition it has 
shown improvement in morbidity of EHT patients.
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Objectives: The purpose of this study is to examine whether there is quality dif-
ferences among AMI patients by severity of cases and by payers status. MethOds: 
The Study examined the outcome differences of acute myocardial infarction (AMI) 
at the National Cardiovascular Center (NCC) Harapan Kita, Jakarta, Indonesia. This 
study analyzed medical records of patients with AMI during the period of January 
1, 2009 until December 31, 2012. Results: The study found 5,472 patients with AMI 
consisting of 81.5% males and 18.5% females with the mean age of 56.3 years (range 
between 21-97 years vs. 26-96 years). Most of the patients were from Jakarta (51%). 
On severity levels, 46% patients were in severity level I, 47.7% severity level II, and 
5.9% level III. More than half (54.6%) patients were treated with intervention (PTCA) 
or surgical procedures (CABG), while 44.4% patients were treated conventionally. We 
found that 43.7% of patients were covered by public insurance, and only 2.9% were 
on Medicaid. The average length of stays was 7.7 days and 87.8% were discharged in 
a good recovery. There was no difference in quality of treatment by difference payers 
or payment system although there was significant discrepancies in charges among 
difference payers. cOnclusiOns: It is concluded that the doctors provided the 
same quality of services among AMI patients, regardless of payers’ status or charges. 
There was no difference in outcome of care among different payers.
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Objectives: Calcium channel blockers are drugs of first choice in the treatment 
of hypertension. The aim of this study was to analyze the consumption of calcium 
channel blockers in Serbia in the period from 2008 to 2012 year. MethOds: The 
data about the use of drugs were taken from the Agency for Drugs and Medical 
Devices of the Serbia. Results: The most frequently used drug from this group 
with mainly vascular effects was amlodipine. During this observed five years the 
consumption of amlodipine is in steadily increased. In 2008. it was 32.00 DDD/1000 
inh/day, at the end of 2011. year the consumption reached it maximum and it 
ranged 72.97 DDD/1000 inh/day. In 2012. the consumption of this drug records 
small fall, and it ranged 66.64 DDD/1000 inh/day.On the second place in drug 
consumption in the same group of drugs was nifedipine. Contrary to amlodipine, 
nifedipine records a decline in consumption. From the calcium channel blockers 
with direct cardiac effects the most frequently used drugs were verapamil and 
diltiazem. The consumption of verapamil in the observed years was uneven. At 
the and of 2012. consumption of this drug was reduced by 50%. The consumption 
of diltiazem in observed five years is in constantly decreasing. cOnclusiOns: 
In Serbia, in the observed period the consumption of calcium channel blockers 
been uneven. In 2011. and 2012. the consumption of calcium channel blockers 
marks a positive trend. This research was supported by Provincial Secretariat 
for Science and Technological Development, Autonomous Province of Vojvodina 
project No 114-451-2458/2011 and by Ministry of Science, Republic of Serbia, pro-
ject no 41012.
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Objectives: Beta blocking agents are drugs of first choice in the treatment of 
hypertension. The aim of this study was to analyze the consumption of beta block-
ing agents in Serbia in the period from 2008 to 2012 year. MethOds: The data 
about the use of drugs were taken from the Agency for Drugs and Medical Devices 
of the Serbia. Results: During the observed period in Serbia the consumption 
of selective beta blocking agents were dominant. The most frequently used drug 
from this group was metoprolol. During this five years the consumption of meto-
prolol is in steadily decreased. In 2008. it was 33.32 DDD/1000 inh/day, at the end 
of 2012. year the consumption was 22.09 DDD/1000inh/day. On the second place 
in drug consumption in the same group of drugs was atenolol, but only in 2008. 
From 2009-2012, atenolol records a decline in consumption and bisoprolol takes 
the second place in drug consumption in that period. At the beginning of 2008. 
consumption of this drug was small, gradually grew and reached its maximum 
in 2012, and it ranged 20.64 DDD/1000inh/day. From the unselective beta blocking 
agents the most frequently used was propranolol and his consumption in the 
observed years was constant. cOnclusiOns: In Serbia, in the observed period 
the consumption of beta blocking agents been mostly constant. From all drugs in 
group of beta blocking agents the most frequently used are metoprolol, atenolol, 
follow-up duration and catheter, so uncertainty may exist regarding overall therapy 
effectiveness. The objective of this analysis is to conduct a systematic review and 
direct meta-analysis of relevant RDN studies to provide a more powerful estimate of 
the true effect size to inform clinical decisions and economic evaluations. MethOds: 
RDN publications were identified through MEDLINE, EMBASE and Cochrane databases 
and manual searching (June 2013). Pre-specified inclusion criteria identified all studies 
(regardless of catheter used) enrolling TR-HTN patients (SBP ≥ 160 mmHg despite > 3 
anti-hypertensive drugs including a diuretic). Results were presented as weighted 
mean decrease (WMD) in office-based SBP over 6 months. Results: A total of 57 
trials were identified (1 RCT, 11 case control, 16 single arm, 29 case series), yielding 
28 studies (n= 896) for meta-analyses. All were open label and reported significant 
reductions in systolic and diastolic blood pressure. The overall WMD in SBP from all 
studies was -28.1 mmHg (95% CI: -24.5 to -31.6). Analysis of only comparative trials 
produced a reduction from baseline SBP ranging from -31.7 mmHg (95% CI: -25.26 
to -38.14) in the RCT (n= 49) to -26.75 mmHg (95% CI: -22.19 to -31.31) for the pooled 
case control trials (n= 56). cOnclusiOns: Over 6 months, RDN was associated with 
substantial SBP reductions in patients with TR-HTN. However, the majority of eligible 
trials were non-randomised, unblinded and used the Symplicity catheter. This may 
have influenced the magnitude of the treatment effect observed.
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Objectives: The paper is to compare the difference between S-Amlodipine and 
racemic amlodipine by using respective cost-effectiveness analysis MethOds: 
the authors use two head-to-head multi-center, RCT studies’ clinical efficacy data, 
Levamlodiping Besylate tablets (Shiweida® 2.5 mg/day) was selected as test group 
and Amlodipine Besylate tablet (Norvasc® 5mg/day) , as a control group. The blood 
pressure and cost of drug were compared in short-term (8 weeks) and long-term 
(6 months) therapeutic regimes. Results: After 4-8 weeks treatment, there was 
no statistical significant difference in efficacy rate between S-Amlodipine group 
(110cases) and racemic Norvasc group (104 cases) 84.91% vs. 77.45%. The cost of 
reducing 1 mmHg systolic pressure and diastolic pressure in S-Amlodipine group 
was 8.1Yuan (RMB) and 10.5Yuan (RMB), and Norvasc group was 16.9Yuan (RMB) 
and 21.7Yuan (RMB), respectively. The cost of Norvasc is 100% higher than that of 
S-Amlodipine. In the results of 6-month long-term treatment, The cost of reduc-
ing 1 mmHg systolic pressure and diastolic pressure in S-Amlodipine group (124 
cases) was 31Yuan (RMB) and 43Yuan (RMB), and 50Yuan (RMB) and 75Yuan (RMB) 
in Norvasc group (104 cases) , respectively. The cost of Norvasc is 1.62-1.79 times 
higher than that of S-Amlodipine. Meanwhile, the study shows that the cost of 
reducing 1mmHg diastolic blood pressure is much higher than that of reducing 
1mm Hg systolic blood pressure. The adverse reaction of S-Amlodipine group (4.6%) 
is significantly lower than Norvasc group (10.3%). The sensitivity analysis based on 
average price and medium price of two-cluster products in China, the S-Amlodipine 
has more economic value. cOnclusiOns: The domestic product of S-Amlodipine 
is more cost-effectiveness than the original Norvasc product. At present, the market 
volume and value of S-Amlodipine in total CCB market is about 30 percent. The 
authors suggest to do further postmarketing clinical trial and parallel prospective 
pharmacoeconomic evaluation to collect more strong basis of evidence.
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Objectives: The current investigation is aimed to understand the impact of 
medication adherence on reasons for non adherence and adherence and control 
of disease, in diabetes mellitus (DM) with hypertension (HTN) patients Morisky 
medication adherence scale (MMAS). MethOds: In this prospective observational 
study, the inclusion criteria for patients to be enrolled are condition of DM with 
HTN comorbidity and patients taking same medication since last two months. 
Patients with DM along with more than two comorbidities were excluded from 
the study. The demographic details (patient name, age, sex, occupation, patient 
income, address, social history, family history, physical activities) and MMAS, blood 
pressure, fasting blood sugar (FBS) and post lunch blood sugar (PLBS) levels were 
collected from the enrolled patients. Reasons for non adherence were recorded 
from low adherence patients. Results: During the study total 300 patients were 
reviewed of which only 128 (42.66%) patients were enrolled into study among them 
63 (49.3%) were male and 65 (50.7%) were female. According to MMAS, patients 
with high adherence were 39 (30.4%), medium adherence was 30 (23.4%), and low 
adherence was 59 (46%). The reasons for lack of adherence in low adherence patients 
are low socioeconomic status (18%), lack of knowledge about impact of non adher-
ence on medication (16%), followed by patients negligence (12%) and others (13%). 
However the results of all the therapeutic outcomes in the study like average blood 
pressure (mmHg), average FBS (mg/dl) and average PLBS (mg/dl) in high adherence, 
medium adherence and low adherence patients showed variation based on degree 
of adherence. cOnclusiOns: The adequate adherence of medication is the prior 
therapeutic option to control DM with HTN patients.
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Objectives: To evaluate the awareness of hyperlipidemia among university stu-
dents and university staff members and to identify respondent variables that affect 
hyperlipidemia knowledge level. MethOds: A survey was conducted to evaluate 
the awareness of hyperlipidemia among university students and faculty members. 
A validated questionnaire was used to assess knowledge of factors that are respon-
sible for hyperlipidemia, knowledge of food that was responsible for hyperlipidemia 
and the knowledge regarding hyperlipidemia medicine. Respondents variables were 
associated with their knowledge level and were evaluated through SPSS version 
20. Results: Of the 205 respondents, 91 (44.2%) were male and 114 (55.8%) were 
females with a mean age of 26.8 years (SD 0.6). One hundred and thirty (63.6%) of 
respondents were students whereas 75 (36.4%) respondents were university staff 
members. Almost half (49.5%) of respondents BMI was normal (18.5-22.5) followed 
by pre-obese (25.7%) and obese (12.1%). One hundred and forty three (69.4%) of 
respondents had adequate knowledge of factors responsible for hyperlipidemia, 190 
(92.2%) had adequate knowledge of food responsible for hyperlipidemia, however 
only 7 (3.4%) respondents had adequate knowledge of hyperlipidemia medicine 
(HMG CoA reductase inhibitors). Respondent gender (p 0.004), education level (p 
0.016) and occupation (p 0.001) had a statistically significant association with factors 
responsible for hyperlipidemia. Respondent’s race (p 0.012) had a significant asso-
ciation with knowledge of food responsible for hyperlipidemia. Similarly, patient 
gender (p 0.046) and occupation (p 0.041) had significant association with knowl-
edge of hyperlipidemia medicine. cOnclusiOns: Awareness of hyperlipidemia 
was adequate among university students and staff members however awareness 
of hyperlipidemia medicine was inadequate. Regular seminars and workshops can 
help create awareness among different aspect of hyperlipidemia.
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Objectives: Stroke is a leading public health problem in terms of mortality and 
economic burden in Korea. Anticoagulants are the mainstay for ischemic stroke 
prevention in atrial fibrillation (AF), but many patients have contraindications to 
these drugs. A number of catheter-based left atrial appendage occlusion (LAAO) 
devices devised to eliminate the major cause of thromboembolism in AF patients 
have been commercialized in Europe but are not yet available in Korea. The pur-
pose of this study is to perform a budget impact analysis of LAAO in patients with 
AF contraindicated to anticoagulation. Such analysis could help decision makers 
assign greater priority to stroke prevention in Korea. MethOds: A budget impact 
model (BIM) was developed based on the number of ischemic strokes and deaths 
prevented by LAAO. LAAO was compared to no stroke prevention since AF patients 
contraindicated to anticoagulation have no other alternatives. Sensitivity analyses 
on clinical and cost inputs were performed. Results: LAAO demonstrated a benefit 
in terms of ischemic strokes and mortality avoided. The BIM was most sensitive to 
the patients’ baseline stroke risk factors, the treatment effect of LAAO, the cost of 
stroke management and the cost of the LAAO procedure. For instance, in high stroke 
risk patients with CHADS2VASc score ≥ 6 one stroke can be avoided within five years 
by LAAO performed in just three patients. LAAO can become cost saving after three 
years post LAAO procedure assuming that the cost of LAAO procedure is approxi-
mately ₩15,000,000, the total cost of stroke defined as direct and indirect cost in the 
first year is approximately 31,000,000 and the total cost in each subsequent year is 
approximately 12,500,000. cOnclusiOns: This analysis highlights that LAAO can 
be a cost saving stroke prevention therapy in anticoagulation intolerant AF patients 
in medium to long term post LAAO procedure.
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Objectives: To examine the medical costs during the first and the 2nd year fol-
lowing the onset of cardiovascular diseases, i.e. myocardial infarction (MI), angina, 
stroke, coronary heart failure (CHF), or peripheral arterial disease (PAD). MethOds: 
The National Health Insurance Research Database (NHIRD), a nationwide popu-
lation-based claims database, was used in the study. Patients who hospitalized 
with the principal diagnosis code of 410 for MI, 413 for angina, 430-434 for stroke, 
or 428 for CHF, or who had outpatient visits with the principal diagnosis of 443.9 
for PAD during 2005-2009 were identified as study subjects. The initial date of the 
hospitalization/outpatient visit with the diagnosis code associated with each dis-
ease was defined as the index date. Patients who had outpatient visits or hos-
pitalization with diagnoses of MI, angina, stroke, CHF and PAD within five years 
before the index date were excluded, except for patients who had outpatient visits 
within two weeks prior to the index date. Patients who withdrew from the health 
insurance program during the first and the 2nd year after the index date were also 
excluded. The generalized linear model was used to estimate medical costs associ-
ated with cardiovascular diseases within 1st year and 2nd year after the index date. 
All costs were inflated to 2011 dollars by using the medical care component of the 
Consumer Price Index. Results: The 1st year average total medical costs associated 
with MI, angina, stroke, CHF, and PAD were NT$293,995, NT$60,305, NT$141,086, 
bisoprolol and nebivolol. This research was supported by Provincial Secretariat 
for Science and Technological Development, Autonomous Province of Vojvodina 
project No 114-451-3551/2013-01 and by Ministry of Science, Republic of Serbia, 
project no 41012.
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Objectives: Catheter-based renal denervation (RDN) has emerged as a new 
therapy option for patients with treatment resistant hypertension (TR-HTN). 
However, inconsistency in the definition and prevalence estimates of TR-HTN has 
the potential to cause confusion with regards to: (1) identifying patients who may 
be eligible for RDN; (2) therapeutic options before consideration for RDN; and (3) 
estimates of potential budget impact. The objective of this analysis is to provide an 
evidence-based estimate of the prevalence of severe TR-HTN to determine the RDN 
eligible patient population in Australia. MethOds: Based on published consensus 
guidelines criteria, severe treatment HTN was defined as SBP ≥ 160 mm Hg despite 
receiving 3 or more anti-HTN drugs including a diuretic. Published prevalence of 
Australians with treated HTN was combined with evidence extracted from the lit-
erature regarding HTN severity, medication usage and clinical trial exclusion rate 
to estimate the number of RDN eligible patients in Australia. Results: In the most 
recent published national assessment, the gross prevalence of HTN in Australia was 
estimated as 34%, with a treatment rate of 53%. The current analysis estimated the 
prevalence of severe TR-HTN amongst treated HTN to be 3.5%. When exclusion 
criteria for RDN were applied, the eligible population was estimated at 1.1% of 
those receiving treatment for HTN. cOnclusiOns: RDN eligible patients represent 
a small and discrete subset of all patients receiving HTN treatment and, when the 
consequences in this high risk population are considered, would represent a moder-
ate impact on government health budgets. In addition, applying standardised and 
clinically based RDN selection criteria may lead to increased scrutiny and improved 
clinical management in the broader pool of HTN patients – some of whom may 
achieve a sufficient reduction in SBP without the need for RDN.
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Objectives: Masked hypertension is associated with an increased risk for car-
diovascular conditions. The aim of the study was to evaluate the relationship 
obesity parameters, including body weight, waist circumference, body mass 
index. MethOds: The study group consisted of 118 consecutive patients with 
masked hypertension and 115 healthy control subjects. After a complete medical 
history and laboratory examination, patients’ height, weight, waist circumference 
heart rate, and office blood pressure were recorded. All subjects underwent ambula-
tory blood pressure monitoring. Masked hypertension is defined as normal office 
blood pressure measurement and high ambulatory blood pressure level. Results: 
Baseline characteristics in patients and controls were similar. Waist circumference 
(93.5±12.4 vs. 87.5±8.5, P< 0.001), weight (79.7±11.4 vs. 68.3±9.9, P< 0.001), body mass 
index (29.9±3.7 vs. 25.1±4.6, P< 0.001) in masked hypertensive subjects was signifi-
cantly higher than controls. cOnclusiOns: This study demonstrated that anthro-
pometric indices such as waist circumference, body mass index were higher in 
masked hypertensive patients. It can be suggested that predefining obesity might 
be helpful in early detection of masked hypertension.
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Objectives: There is considerable literature from developed nations on the effect 
of body mass index (BMI) on outcomes following cardiac surgery. Increased BMI is 
associated with an increased postoperative morbidity. World health organization 
(WHO) has suggested modified scale for Asians to categorize BMI. We have studied 
the effect of BMI on our population, using modified scale, as predictor of outcome 
after coronary artery bypass grafting (CABG). MethOds: 1019 charts of first time 
isolated elective CABG patients was retrospectively reviewed from January 2006 
to December 2008. We excluded patients undergoing urgent, emergency and off 
pump procedures. Data was analyzed on SPSS17. Logistic regression was applied 
to explore whether increased BMI is a predictor of in- hospital complications after 
CABG. Results: Retrospective analysis of 1019 first time isolated elective CABG 
patients was performed. Out of them, 163(16.0%) patients had normal BMI (18.5 to 
22.9 (kg/m2) while 856(84.0%) had increased BMI (≥ 23.0 (kg/m2). Operative profile 
shows that (888 (87.%)) patients had three vessels coronary artery disease and (970 
(95.2%)) got IMA grafts. Their 30-days mortality was 0.8%. The data showed patients 
with higher BMI tended to have increased postoperative complications. However 
multivariate analysis revealed age (adj OR: 1.04; 95%C.I: 1.02, 1.06), hospital stay (adj 
OR: 1.07; 95% C.I: 1.04, 1.10), perfusion time (adj OR: 1.48; 95%C.I: 1.05, 2.10) and renal 
failure (adj OR: 1.63; 95% C.I: 1.02, 2.59) as significantly associated with in hospital 
complications, while increased BMI remained insignificant at P value of ≤ 0.05. Model 
was adequately fit at P= 0.749 by Hosmer and Lemeshow test. cOnclusiOns: This 
study concludes that increased BMI in itself is not a predictor of increased mortal-
ity and morbidity. Post-operative complications in first time isolated elective CABG 
patients is, in fact, associated with increasing age, hospital stay, perfusion time 
and renal failure.
